Full Text View
Tabular View
No Study Results Posted
Related Studies
Effects of Raloxifene on Hormone Levels
This study has been completed.
Study NCT00026962   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 14, 2001   Last Updated: March 3, 2008   History of Changes

November 14, 2001
March 3, 2008
September 1999
 
 
 
Complete list of historical versions of study NCT00026962 on ClinicalTrials.gov Archive Site
 
 
 
Effects of Raloxifene on Hormone Levels
Assessment of the Effects of Raloxifene on Salivary Estradiol and Progesterone Levels

Blood levels of the hormones estradiol and progesterone are of interest in evaluating ovarian function. However, because these hormone levels vary from day to day, blood samples must be taken very often or elaborately timed to specific phases of the menstrual cycle. A method has now been developed for measuring estradiol and progesterone levels in saliva. This study will test the accuracy of this method and examine whether salivary levels of these hormones change after treatment with raloxifene.

Hormone levels will be measured during 3 menstrual cycles in women currently enrolled in the clinical study, "A Phase II Trial of Two Doses of Raloxifene in Women at Risk of Developing Invasive Breast Cancer." Participants will provide a saliva sample every morning for about a month during three collection periods-1 month before beginning raloxifene treatment, and 3 and 12 months after treatment starts. Patients will be given kits for collecting the samples and mailing them to the laboratory at the end of each collection period.

Deviations from normal levels of serum E(2) and P are of interest in evaluating ovarian function. However, the day-to-day variations in these levels necessitates serial blood sampling or elaborate efforts to time blood draws within specific phases of the menstrual cycle. A noninvasive method for assessment of the levels of sex steroids on a daily basis using saliva has been developed. This study will assess the levels of estradiol and progesterone during 3 menstrual cycles (pre-drug and after 3 and 12 months of raloxifene therapy) in pre-menopausal women participating in a pilot chemoprevention trial of raloxifene.

Phase II
Interventional
Treatment, Safety/Efficacy Study
Breast Cancer
Procedure: measuring estradiol and progesterone levels in saliva
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
60
August 2003
 

Patients must be enrolled on protocol 98-C-0123 (MB #402) or this same protocol at the National Naval Medical Center.

Female
 
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00026962
 
990180, 99-C-0180
National Cancer Institute (NCI)
 
 
National Institutes of Health Clinical Center (CC)
August 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP